Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
118.42
-4.54 (-3.69%)
At close: Sep 12, 2025, 4:00 PM EDT
118.99
+0.57 (0.48%)
After-hours: Sep 12, 2025, 6:27 PM EDT
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $150.04M in the quarter ending June 30, 2025, with 72.13% growth. This brings the company's revenue in the last twelve months to $495.03M, up 69.83% year-over-year. In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth.
Revenue (ttm)
$495.03M
Revenue Growth
+69.83%
P/S Ratio
11.66
Revenue / Employee
$724,792
Employees
683
Market Cap
5.91B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
Dec 31, 2022 | 50.04M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AXSM News
- 4 days ago - Axsome Therapeutics, Inc. (AXSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 17 days ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings - Benzinga
- 5 weeks ago - Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy - Seeking Alpha
- 7 weeks ago - Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - GlobeNewsWire
- 2 months ago - Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 - GlobeNewsWire